ImmUniverse
LAUFZEIT:
01/2020
—
Projektlaufzeit gesamt:
5 Jahre
Das Projekt
Immun-mediierte Entzündungskrankheiten (IMIDs) nehmen in den Industrieländern weltweit zu. Ein tiefgreifendes Verständnis der gemeinsamen Krankheitsmechanismen durch molekulare Profile ist für künftige Strategien der Präzisionsmedizin für IMIDs unerlässlich.
Unsere Tätigkeiten im Projekt
HEALTH trägt mit seinen Kerntechnologien – dermale OFM und Metabolomics – zur internationalen Erforschung von Entzündungs- und Autoimmunerkrankungen bei.
Forschungsgruppen
Downloads
Auftraggeber
Projektpartner
Coordinator: Humanitas University, Italy
Project Lead: GlaxoSmithKline Research & Development Limited, UK
Details zum Projekt
ImmUniverse – Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies
ImmUniverse is being performed by a European transdisciplinary consortium of 26 partners to pave the way towards a truly personalised understanding of two different IMIDs: Ulcerative Colitis and Atopic Dermatitis.
As a project partner, HEALTH supports the international consortium in identifying biomarker pattern and mechanistic principles with its two core technologies – dermal OFM and metabolomics. With these methods, the molecular fingerprint of the diseases is investigated in different tissues. These molecular data in combination with data on disease severity and progression from several clinical studies will lead to personalised therapy decisions.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853995. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Read more: www.immuniverse.eu
